人附睾蛋白4及癌抗原125在盆腔包块性质鉴别中临床应用.docVIP

人附睾蛋白4及癌抗原125在盆腔包块性质鉴别中临床应用 　　[摘要] 目的 研究人附睾蛋白4（HE4）及癌抗原125（CA125）在盆腔包块性质鉴别中的临床应用价值。 方法 将2012年3月～2014年3月广州市妇女儿童医疗中心（以下简称“我院”）收治的卵巢癌和卵巢良性肿瘤患者各100例纳入研究，将其分别作为卵巢癌组和卵巢良性肿瘤组，同时将同期在我院体检的健康者纳入研究的健康对照组。比较三组受试者的血清HE4及CA125，分析灵敏度、特异性、阳性预测值、阴性预测值。 结果 卵巢良性肿瘤组与健康对照组患者的血清HE4、CA125含量比较，差异无统计学意义（P 0.05）；卵巢癌组血清HE4和CA125[（154.56±20.41）μmol/L、（251.52±39.52）U/mL]含量高于卵巢良性肿瘤组[（35.52±5.62）μmol/L、（48.52±1.94）U/mL]和健康对照组[（33.48±4.95）μmol/L、（42.48±5.62）U/mL]，差异均有高度统计学意义（t=57.662、56.241；50.97、52.368；均P 　　[关键词] 盆腔包块；卵巢癌；人附睾分泌蛋白；癌抗原125 　　[中图分类号] R737.31 [文献标识码] A [文章编号] 1673-7210（2014）11（b）-0030-04 　　[Abstract] Objective To study the clinical application value of HE4 and CA125 in qualitative distinctions of pelvic mass. Methods 100 cases of ovarian cancer and 100 cases of benign ovarian tumor from March 2012 to March 2014 in Women and Childrens Medical Center of Guangzhou City （“our hospital” for short） were enrolled， and they were divided into ovarian cancer group and benign tumor group respectively， healthy subjects received physical examination in the same period in our hospital were enrolled as healthy control group. Then serum HE4 and CA125 content were compared， and the sensitivity， specificity， positive predictive value， negative predictive value were analyzed. Results There were no statistically difference of serum HE4 and CA125 between benign ovarian cancer group and healthy control group （P 0.05）； the serum HE4 and CA125 levels of ovarian cancer group [（154.56±20.41） μmol/L， （251.52±39.52） U/mL] were significantly higher than benign ovarian tumor group [（35.52±5.62） μmol/L， （48.52±1.94） U/mL] and the healthy control group [（33.48±4.95） μmol/L， （42.48±5.62） U/mL]， the differences were statistically significant （t=57.662， 56.241； 50.97， 52.368； all P 　　[Key words] Pelvic mass； Ovarian cancer； HE4； CA125 　　盆腔包块是女性常见疾病，需要采取必要的手段来对包块性质进行鉴别。癌抗原125（CA125）是临床上用于鉴别良恶性肿瘤的常用肿瘤标志物，但是单独检测的灵敏度和特异性并不理想[1]。人附睾分泌蛋白（HE4）是近年来发现的一类蛋白，与卵巢癌的发生发展密切相关，对于良恶性肿瘤的鉴别具有一定价值[2]。本研究分析了HE4及CA125在盆腔包块性质鉴别中的临床应用价值。